Keyphrases
Cost-effectiveness
100%
United States
100%
Gene Therapy
100%
Sickle Cell Disease
100%
Cost-effectiveness Analysis
55%
Standard of Care
44%
Quality-adjusted Life Years
44%
Equity Weighting
33%
Incremental Cost-effectiveness Ratio
22%
Inequity Aversion
22%
Treatment Effect
11%
Claims Data
11%
Sensitivity Analysis
11%
Disease-specific
11%
Therapeutic Strategies
11%
Living with
11%
Markov Model
11%
Life-years Gained
11%
Birth Cohort
11%
US Healthcare System
11%
Willingness-to-pay Threshold
11%
Specific Weight
11%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Sickle-Cell Disease
100%
Gene Therapy
100%
Carcinoembryonic Antigen
50%
Quality Adjusted Life Year
50%
Health Care Cost
37%
Lifespan
25%
Patient with Sickle Cell Disease
25%
Aversion
25%
Base
12%
Health System
12%